About GLP-1s Explained
What this encyclopedia covers, who writes it, which sources every number is checked against, and how to reach the editorial team.
GLP-1s Explained is a reference work, not a magazine. One entry per agent, the same headings on every entry, and a source named beside every number.
What the site covers
Thirteen entries. Nine agents have an FDA approval on record: semaglutide by injection and by tablet, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide, albiglutide and orforglipron. Two of those, exenatide and albiglutide, are listed as discontinued in Drugs@FDA. Four agents are still investigational in the United States: retatrutide, survodutide, CagriSema and mazdutide. Around the entries sit four guides (how the class works, approved against investigational against compounded, the approval timeline, and a glossary) and one tool, the agent comparison table, which puts up to four entries side by side.
Who writes it
The FormBlends editorial team, which also publishes formblends.com. FormBlends runs a GLP-1 weight-loss program that dispenses compounded semaglutide and tirzepatide through licensed pharmacies. That is a commercial interest and it is disclosed here, in the footer of every page, and wherever a page links to a FormBlends product. Compounded products are not FDA approved and are not interchangeable with the brand products this site describes. Nothing on this site is written by, or reviewed by, a named clinician, and we do not claim otherwise.
How each entry is checked
Every entry is built from three primary sources and nothing else:
- Drugs@FDA for application numbers, approval dates, marketing status, and the approval letters that say what a supplement added. Where a letter is posted we read it; where only the date and the class of supplement are listed we say so.
- The current prescribing information on DailyMed, or the FDA-approved label PDF when a product is no longer on DailyMed, for mechanism, indications, dosing, the boxed warning, and the adverse-reaction table. Adverse-reaction rates are copied from the placebo-controlled table in section 6.1 of each label, with the placebo column and the sample sizes.
- PubMed for each pivotal trial: we cite the PubMed id and take the headline numbers from the abstract. Where an abstract reports kilograms and we show a percent, the derivation is written next to the number.
If a number could not be found in one of those sources, it is not on the site. Company press releases, news coverage and secondary summaries are not used as sources for numbers. Each page carries the date the sources were last checked; when a label changes, the page changes and the date moves.
Editorial rules
No reviews, testimonials or star ratings. No fabricated clinicians and no "medically reviewed by" claims. No ranking of agents, and no recommendation of one over another; the comparison table shows what each label and trial reports and reminds you that numbers from different trials are not directly comparable. FAQ sections contain only questions that are answered on the page they sit on. The prose avoids the em dash and reads the way a careful colleague would speak.
What this site is not
It is not medical advice and it does not decide who should take what. Dosing tables reproduce label wording so you can read the label with understanding, not so you can dose from a web page. Talk to a prescriber and a pharmacist. Read the medical disclaimer.
Contact
Corrections, missing sources and requests for new entries go to hello@formblends.com. Quote the page URL and the exact sentence. Errors of fact are fixed as a priority and the fix is noted on the page.
Sources
- Drugs@FDA: FDA-approved drugs Accessed September 4, 2026.
- DailyMed, National Library of Medicine Accessed September 4, 2026.
- PubMed, National Library of Medicine Accessed September 4, 2026.
- FDA: Human Drug Compounding Accessed September 4, 2026.